Table 3.

Administered CINV prophylaxis and observed CINV symptoms during treatment

ID	CINV prophylaxis during treatment*	CINV rescue medication	CINV symptoms during treatment**				CINV score***
			Nausea	Vomiting	Appetite/intake	Weight loss
1	No		-	-	-	-	0
2	No		n.a.	n.a.	-	-	0
3	1		±	±	+	-	2
4	1		+  +	+  +	n.a.	n.a.	4
5	1		+	-	+	+	3
6	1	MCP 0.5 mg/kg/day	+  +	+  +	±	+	5
7	1		-	+	n.a.	-	1
8	1		+  +	+  +	±	+	5
9	1		+	-	-	-	1
10	1		+  +	+	-	-	3
11	1		+  +	+	+	-	4
12	2		±	±	±	±	2
13	3		+	±	±	+	3
14	3	MCP 0.6 mg/kg/day	+  +	+  +	+	-	5
15	3		+	+	+	+	4
16	3		+  +	-	-	-	2
17	3		-	±	±	+	2

MCP metoclopramide

*1, 5-HT3 receptor antagonist; 2, 5-HT3 receptor antagonist + dexamethasone; 3, 5-HT3 receptor antagonist + (fos)aprepitant +/- dexamethasone

**- none, ± mild, + moderate, +  + severe, n.a. not available

***CINV score 0 and 1, none to mild; 2 and 3, moderate; 4 and 5, severe. Based on CINV symptoms during treatment, CINV prophylaxis during treatment, and score of primary care provider